- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.11. | Earnings call: Bioventus reports robust Q3 growth, raises full-year guidance | 1 | Investing.com | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 06.11. | Telefonkonferenz zu Quartalszahlen: Bioventus meldet robustes Wachstum im dritten Quartal und erhöht Prognose für das Gesamtjahr | 1 | Investing.com Deutsch | ||
| 05.11. | Bioventus, Inc.: Bioventus Reports Third Quarter Financial Results | 101 | GlobeNewswire (Europe) | Q3 Revenue Advanced by 15.0%, Fourth Straight Quarter of Double Digit Organic* GrowthQ3 Gross Margin Expanded 200 bpsQ3 Cash from Operations of $10.3 million, an Increase of $18.6 million Compared... ► Artikel lesen | |
| 05.11. | Bioventus Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.10. | Bioventus stock soars to 52-week high, hits $13.65 | 3 | Investing.com | ||
| 29.10. | Bioventus, Inc.: Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 | 1 | GlobeNewswire (USA) | ||
| 25.10. | Bioventus files for $200M mixed securities shelf | 1 | Seeking Alpha | ||
| 23.10. | Bioventus stock soars to 52-week high, hits $13.14 | 1 | Investing.com | ||
| 14.10. | Bioventus-Aktie erreicht 52-Wochen-Hoch von 12,43 US-Dollar | 1 | Investing.com Deutsch | ||
| 11.10. | Bioventus (NYSE:BVS) Trading Up 7.5% - Here's What Happened | 2 | MarketBeat | ||
| 04.10. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | Canaccord Genuity hält an Kaufempfehlung für Bioventus fest | 2 | Investing.com Deutsch | ||
| 01.10. | Bioventus maintains Buy rating by Canaccord Genuity | 2 | Investing.com | ||
| 01.10. | Bioventus announces divestiture of its Advanced Rehabilitation business to Accelmed Partners | 1 | Seeking Alpha | ||
| 27.09. | Bioventus (NYSE:BVS) Sets New 12-Month High After Analyst Upgrade | 1 | MarketBeat | ||
| 27.09. | Bioventus (NYSE:BVS) Price Target Increased to $17.00 by Analysts at Craig Hallum | 1 | MarketBeat | ||
| 18.09. | Bioventus-Aktie erreicht 52-Wochen-Hoch bei 11,49 US-Dollar | - | Investing.com Deutsch | ||
| 18.09. | Bioventus stock soars to 52-week high, hits $11.49 | 1 | Investing.com | ||
| 09.09. | Bioventus stock soars to 52-week high, hits $10.26 | 1 | Investing.com |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,402 | -0,99 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,950 | -1,65 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | +0,41 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,740 | -0,24 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data | ||
| ARCTURUS THERAPEUTICS | 16,340 | -1,15 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,881 | +0,60 % | Assertio Holdings, Inc.: Assertio Announces Results of Rolvedon (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study | LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,390 | -0,11 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,980 | -0,33 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,430 | +0,68 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,300 | -1,81 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,785 | +0,26 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,940 | -0,32 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,030 | -0,96 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
Das Unternehmen BIOVENTUS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 10,690 Euro und damit +0,09 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.
